cannabis indica

Insuficiência Renal

termo de indexação original: Kidney Failure

O acervo do Cannabis Indica reúne 67 estudos científicos que tocam a condição Insuficiência Renal, publicados entre 2009 e 2024. Pela leitura automatizada, 41 (61%) foram classificados como favoráveis, 9 (13%) como inconclusivos e 17 (25%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (31 estudos), seguido de ensaio clínico (22). Os compostos mais presentes são Proteína Ligadora de Ácidos Graxos (FABP), Anandamida (AEA) e Canabinoide Sintético (não especificado). Aparece com frequência ao lado de Doenças Cardiovasculares (DCV), Inflamação e Doença Renal Crônica.

Estudos indexados
67
Período coberto
2009–2024
Favoráveis
41 · 61%
Inconclusivos
9 · 13%
Desfavoráveis
17 · 25%
Termo original
Kidney Failure

O acervo em números

Tipo de estudo

Metanálise31
Ensaio Clínico22
Estudo em Animais5
Estudo Laboratorial4
Ensaio Clínico Duplo-Cego4
Metanálise Clínica1

Direção do resultado

Favorável41
Inconclusivo9
Desfavorável17

Por década

2000s1
2010s31
2020s35

67 estudos

Filtrar e buscar no acervo →
  1. 2024

    Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present)

  2. 2023

    Cannabidiol-enriched cannabis extraction product in Parkinson's disease: A randomized, double-blind, and placebo-controlled trial in Buriram Hospital

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDepressãoDoença de ParkinsonCBD Farmacêutico+1
  3. 2023

    Cannabis-Induced Acute Encephalopathy in a 94-Year-Old Woman Due to Family Administration of Cannabidiol (CBD) Products: A Case Report

  4. 2023

    Involvement of cannabinoid receptors and neuroinflammation in early sepsis: Implications for posttraumatic stress disorder

  5. 2023

    Perfluorooctane sulfonate-induced apoptosis in kidney cells by triggering the NOX4/ROS/JNK axis and antagonism of cannabidiol

    FavorávelEstudo LaboratorialInflamaçãoEstresse Oxidativo
  6. 2023

    Resolvin E1 heals injured cardiomyocytes: Therapeutic implications and H-FABP as a readout for cardiovascular disease & systemic inflammation

  7. 2023

    Systemic Changes in Endocannabinoids and Endocannabinoid-like Molecules in Response to Partial Nephrectomy-Induced Ischemia in Humans

    FavorávelEnsaio ClínicoAnandamida (AEA)Endocanabinoide (não especificado)+2
  8. 2023

    Urinary liver-type fatty acid-binding protein in two dogs with acquired Fanconi syndrome: A case report

  9. 2023

    Urinary liver-type fatty acid-binding protein: A hemodynamic index during extracorporeal membrane oxygenation

  10. 2022

    Adverse events of recreational cannabis use during pregnancy reported to the French Addictovigilance Network between 2011 and 2020

  11. 2022

    Biomarkers for the early prediction of contrast-induced nephropathy after percutaneous coronary intervention in adults: A systematic review and meta-analysis

  12. 2022

    Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative Review

    DesfavorávelMetanáliseDorInflamaçãoAnsiedade+10
  13. 2022

    Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Proceduresv

  14. 2022

    Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: a systematic review and meta-analysis

    InconclusivoMetanáliseInflamaçãoProteína Ligadora de Ácidos Graxos (FABP)
  15. 2022

    Endocannabinoid System in Polycystic Kidney Disease

  16. 2022

    Kidney Damage and Stress Biomarkers for Early Identification of Drug-Induced Kidney Injury: A Systematic Review

  17. 2022

    Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study

    FavorávelEnsaio Clínico Duplo-CegoDorDor — CrônicaTetraidrocanabinol (THC)
  18. 2022

    Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis

  19. 2022

    Succinylcholine Induced Rhabdomyolysis in a Heavy Marijuana Smoker: A Case Report

    DesfavorávelMetanálise
  20. 2022

    The Medicinal Natural Products of Cannabis sativa Linn.: A Review

  21. 2021

    (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB 1 R antagonist/CB 2 R agonist that prevents diabetic nephropathy in mice

    FavorávelEstudo em AnimaisDorDiabetesSíndrome Metabólica+2
  22. 2021

    [Droghe d'abuso e rene] Drugs of Abuse and the Kidney

  23. 2021

    Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients

    DesfavorávelEnsaio Clínico Duplo-CegoInflamaçãoAnandamida (AEA)Endocanabinoide (não especificado)+4
  24. 2021

    Lethal case of myocardial ischemia following overdose of the synthetic cannabinoid ADB-FUBINACA

  25. 2021

    Nephrologist Views Regarding Cannabinoid Use in Advanced Chronic Kidney Disease and Dialysis: A Survey

    FavorávelMetanáliseCâncerDoença Renal CrônicaNefropatia Diabética+3
  26. 2021

    Phycocyanobilin is the molecule responsible for the nephroprotective action of phycocyanin in acute kidney injury caused by mercury

    FavorávelEstudo em AnimaisFicocianina
  27. 2021

    Suicide by vaping the synthetic cannabinoid 4F-MDMB-BINACA: cannabinoid receptors and fluoride at the crossroads of toxicity?

  28. 2021

    Synthetic Cannabinoids and Cathinones Cardiotoxicity: Facts and Perspectives

  29. 2021

    β-Caryophyllene may attenuate hyperoxaluria-induced kidney dysfunction in rats by regulating stress marker KIM-1/MCP-1 and NF-κB signaling pathway

    FavorávelEstudo em Animais
  30. 2021

    β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19

    InconclusivoMetanáliseInflamaçãoDoenças Cardiovasculares (DCV)Disfunção Cognitiva+7
  31. 2020

    A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment

  32. 2020

    Beyond THC and Endocannabinoids

  33. 2020

    Changes in Novel AKI Biomarkers after Exercise. A Systematic Review

    FavorávelMetanáliseProteína Ligadora de Ácidos Graxos (FABP)
  34. 2020

    P-NGAL Day 1 predicts early but not one year graft function following deceased donor kidney transplantation - The CONTEXT study

  35. 2020

    The nephrologist's guide to cannabis and cannabinoids

    InconclusivoMetanáliseDoença Renal Crônica
  36. 2019

    Can we teach old drugs new tricks?-Repurposing of neuropharmacological drugs for inflammatory skin diseases

    FavorávelMetanáliseInflamaçãoDepressãoEpilepsia+14
  37. 2019

    Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease

  38. 2019

    Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?

  39. 2018

    Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay

    FavorávelEnsaio ClínicoDorInflamaçãoDor — Crônica+1
  40. 2018

    Impact of cannabidiol treatment on regulatory T-17 cells and neutrophil polarization in acute kidney injury

    FavorávelEstudo em AnimaisDoenças Cardiovasculares (DCV)Lesão de Reperfusão
  41. 2018

    Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD

    InconclusivoMetanáliseDoença Renal Crônica
  42. 2018

    The role of cannabinoid signaling in acute and chronic kidney diseases

  43. 2017

    Cannabinoids and the kidney: effects in health and disease

  44. 2017

    Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure

  45. 2017

    Propofol-based anaesthesia versus sevoflurane-based anaesthesia for living donor kidney transplantation: results of the VAPOR-1 randomized controlled trial

  46. 2016

    Cannabinoid receptors in the kidney

    FavorávelMetanálise
  47. 2016

    Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

  48. 2016

    Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor

  49. 2016

    The protective effect of human atrial natriuretic peptide on renal damage during cardiac surgery

  50. 2015

    Clinical Safety of a High Dose of Phycocyanin-Enriched Aqueous Extract from Arthrospira (Spirulina) platensis: Results from a Randomized, Double-Blind, Placebo-Controlled Study with a Focus on Anticoagulant Activity and Platelet Activation

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDor — CrônicaFicocianina+4
  51. 2015

    Combination of biomarkers for diagnosis of acute kidney injury after cardiopulmonary bypass

  52. 2015

    Emerging Therapeutic Targets of Sepsis-Associated Acute Kidney Injury.

    FavorávelMetanáliseAnandamida (AEA)
  53. 2015

    Urine Biomarkers and Perioperative Acute Kidney Injury: The Impact of Preoperative Estimated GFR

  54. 2015

    Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial

  55. 2014

    Acute kidney injury after using contrast during cardiac catheterization in children with heart disease

  56. 2014

    Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22

  57. 2013

    Remote ischemic pre-conditioning alleviates contrast-induced acute kidney injury in patients with moderate chronic kidney disease

  58. 2012

    Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery

  59. 2012

    L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease

  60. 2012

    Renoprotective and antioxidant effects of cilnidipine in hypertensive patients

  61. 2011

    Biomarkers for early detection of sickle nephropathy

  62. 2011

    Cannabinoid hyperemesis syndrome inducing acute prerenal failure and electrolyte disturbance

    DesfavorávelMetanáliseSíndrome da Hiperêmese Canabinoide
  63. 2011

    Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy

  64. 2011

    Is There a Legitimate Role for the Therapeutic Use of Cannabinoids for Symptom Management in Chronic Kidney Disease?

    FavorávelMetanáliseDoença Renal CrônicaTetraidrocanabinol (THC)
  65. 2011

    Myocardial protective effect of human atrial natriuretic Peptide in cardiac surgery. -hANP Shot” in clinical safety trial-

  66. 2011

    Renovascular protective effects of erythropoietin in patients with chronic kidney disease

  67. 2009

    Up-regulation of TRPV1 in mononuclear cells of end-stage kidney disease patients increases susceptibility to N-arachidonoyl-dopamine (NADA)-induced cell death

Continue por aqui

Perguntas frequentes

Quantos estudos sobre insuficiência renal estão indexados no acervo?
São 67 estudos, publicados entre 2009 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 31 · Ensaio Clínico: 22 · Estudo em Animais: 5 · Estudo Laboratorial: 4 · Ensaio Clínico Duplo-Cego: 4 · Metanálise Clínica: 1. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 41 favoráveis, 9 inconclusivos e 17 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Insuficiência Renal — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/insuficiencia-renal/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Insuficiência Renal — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/insuficiencia-renal/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.